Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108


Are women who work in bars, guesthouses and similar facilities a suitable study population for vaginal microbicide trials in Africa?

Vallely A, Hambleton IR, Kasindi S, Knight L, Francis SC, Chirwa T, Everett D, Shagi C, Cook C, Barberousse C, Watson-Jones D, Changalucha J, Ross D, Hayes RJ; Microbicides Development Programme.

PLoS One. 2010 May 14;5(5):e10661. doi: 10.1371/journal.pone.0010661.


Microbicides development programme: engaging the community in the standard of care debate in a vaginal microbicide trial in Mwanza, Tanzania.

Vallely A, Shagi C, Lees S, Shapiro K, Masanja J, Nikolau L, Kazimoto J, Soteli S, Moffat C, Changalucha J, McCormack S, Hayes RJ.

BMC Med Ethics. 2009 Oct 9;10:17. doi: 10.1186/1472-6939-10-17.


A model for community representation and participation in HIV prevention trials among women who engage in transactional sex in Africa.

Shagi C, Vallely A, Kasindi S, Chiduo B, Desmond N, Soteli S, Kavit N, Vallely L, Lees S, Hayes R, Ross D; Microbicides Development Programme.

AIDS Care. 2008 Oct;20(9):1039-49. doi: 10.1080/09540120701842803.


How informed is consent in vulnerable populations? Experience using a continuous consent process during the MDP301 vaginal microbicide trial in Mwanza, Tanzania.

Vallely A, Lees S, Shagi C, Kasindi S, Soteli S, Kavit N, Vallely L, McCormack S, Pool R, Hayes RJ; Microbicides Development Programme (MDP).

BMC Med Ethics. 2010 Jun 13;11:10. doi: 10.1186/1472-6939-11-10.


HIV prevalence and incidence among sexually active females in two districts of South Africa to determine microbicide trial feasibility.

Nel A, Louw C, Hellstrom E, Braunstein SL, Treadwell I, Marais M, de Villiers M, Hugo J, Paschke I, Andersen C, van de Wijgert J.

PLoS One. 2011;6(8):e21528. doi: 10.1371/journal.pone.0021528. Epub 2011 Aug 10.


High HIV prevalence and incidence among women in Southern Mozambique: Evidence from the MDP microbicide feasibility study.

Mocumbi S, Gafos M, Munguambe K, Goodall R, McCormack S; Microbicides Development Programme.

PLoS One. 2017 Mar 28;12(3):e0173243. doi: 10.1371/journal.pone.0173243. eCollection 2017.


Intravaginal and menstrual practices among women working in food and recreational facilities in Mwanza, Tanzania: implications for microbicide trials.

Allen CF, Desmond N, Chiduo B, Medard L, Lees SS, Vallely A, Francis SC, Ross DA, Hayes RJ.

AIDS Behav. 2010 Oct;14(5):1169-81. doi: 10.1007/s10461-010-9750-8.


Pregnancy incidence and risk factors among women participating in vaginal microbicide trials for HIV prevention: systematic review and meta-analysis.

Musekiwa A, Muchiri E, Manda SO, Mwambi HG.

PLoS One. 2013 Oct 10;8(10):e77014. doi: 10.1371/journal.pone.0077014. eCollection 2013. Review.


Microbicides development program, Tanzania-baseline characteristics of an occupational cohort and reattendance at 3 months.

Vallely A, Kasindi S, Hambleton IR, Knight L, Chirwa T, Balira R, Changalucha J, Watson-Jones D, Everett D, Gavyole A, Moyes J, Pujades-Rodríguez M, Ross DA, Hayes RJ.

Sex Transm Dis. 2007 Sep;34(9):638-43.


The epidemiology of HIV and HSV-2 infections among women participating in microbicide and vaccine feasibility studies in Northern Tanzania.

Kapiga SH, Ewings FM, Ao T, Chilongani J, Mongi A, Baisley K, Francis S, Andreasen A, Hashim R, Watson-Jones D, Changalucha J, Hayes R.

PLoS One. 2013 Jul 18;8(7):e68825. doi: 10.1371/journal.pone.0068825. Print 2013.


A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases.

Roddy RE, Zekeng L, Ryan KA, Tamoufé U, Weir SS, Wong EL.

N Engl J Med. 1998 Aug 20;339(8):504-10.


HIV incidence rates and risk factors for urban women in Zambia: preparing for a microbicide clinical trial.

Kapina M, Reid C, Roman K, Cyrus-Cameron E, Kwiecien A, Weiss S, Vermund SH.

Sex Transm Dis. 2009 Mar;36(3):129-33. doi: 10.1097/OLQ.0b013e318190191d.


[Current status of the female condom in Africa].

Deniaud F.

Sante. 1997 Nov-Dec;7(6):405-15. Review. French.


Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda.

Abaasa A, Crook A, Gafos M, Anywaine Z, Levin J, Wandiembe S, Nanoo A, Nunn A, McCormack S, Hayes R, Kamali A.

Trials. 2013 Feb 1;14:33. doi: 10.1186/1745-6215-14-33.


School-based interventions for preventing HIV, sexually transmitted infections, and pregnancy in adolescents.

Mason-Jones AJ, Sinclair D, Mathews C, Kagee A, Hillman A, Lombard C.

Cochrane Database Syst Rev. 2016 Nov 8;11:CD006417. Review.


Intravaginal practices and microbicide acceptability in Papua New Guinea: implications for HIV prevention in a moderate-prevalence setting.

Vallely A, Fitzgerald L, Fiya V, Aeno H, Kelly A, Sauk J, Kupul M, Neo J, Millan J, Siba P, Kaldor JM.

BMC Res Notes. 2012 Nov 1;5:613. doi: 10.1186/1756-0500-5-613.


Barrier contraceptive use and HIV infection among high-risk women in Cameroon.

Zekeng L, Feldblum PJ, Oliver RM, Kaptue L.

AIDS. 1993 May;7(5):725-31.


Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women.

Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, Kapina M, Maslankowski L, Coletti A, Profy A, Moench TR, Piwowar-Manning E, Mâsse B, Hillier SL, Soto-Torres L; HIV Prevention Trials Network (HPTN) 035 Study Team.

AIDS. 2011 Apr 24;25(7):957-66. doi: 10.1097/QAD.0b013e32834541d9.


Enrollment of adolescents aged 16-17 years old in microbicide trials: an evidence-based approach.

Schenk KD, Friedland BA, Chau M, Stoner M, Plagianos MG, Skoler-Karpoff S, Palanee T, Ahmed K, Rathlagana MJ, Mthembu PN, Ngcozela N.

J Adolesc Health. 2014 Jun;54(6):654-62. doi: 10.1016/j.jadohealth.2014.01.014. Epub 2014 Mar 29.


Population-based study of fertility in women with HIV-1 infection in Uganda.

Gray RH, Wawer MJ, Serwadda D, Sewankambo N, Li C, Wabwire-Mangen F, Paxton L, Kiwanuka N, Kigozi G, Konde-Lule J, Quinn TC, Gaydos CA, McNairn D.

Lancet. 1998 Jan 10;351(9096):98-103.


Supplemental Content

Support Center